Replimune Group Inc

Research Replimune Group Inc (REPL) on Bullrun: market cap USD 924.81M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerREPL
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 924.81M
• Financial periodFY2025
• Net income-USD 247.30M
• Free cash flow-USD 198.94M

Valuation Snapshot

latest market cap is USD 924.81M.

About Replimune Group Inc

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.

Frequently asked questions

What is Replimune Group Inc's market cap?

Replimune Group Inc's market capitalization is USD 924.81M.

What does Replimune Group Inc do?

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.